Most participants hit their plateau between weeks 40 and 48, with the average being around week 43
Risk factors There are few known risk factors for uterine fibroids, other than being a person of reproductive age
Manging interactions Tirzepatide may interact with other medications, which can affect their effectiveness or increase the risk of side effects
In SURMOUNT-1, which enrolled adults with obesity or overweight without diabetes, participants receiving tirzepatide 5 mg, 10 mg, or 15 mg weekly achieved mean weight reductions of 15.0%, 19.5%, and 20.9% respectively at 72 weeks, compared to 3.1% with placebo
Compounded semaglutide requires refrigeration and has a limited shelf life after reconstitution